Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1.
Abstract | RATIONALE: OBJECTIVE: In this study, we hypothesized that rivaroxaban's antithrombotic potential is linked to a hitherto unknown rivaroxaban effect that impacts on platelet reactivity and arterial thrombosis. METHODS AND RESULTS: CONCLUSIONS: Here, we identified FXa as potent platelet agonist that acts through PAR-1. Therefore, rivaroxaban exerts an antiplatelet effect that together with its well-known potent anticoagulatory capacity might lead to reduced frequency of atherothrombotic events and improved outcome in patients.
|
Authors | Tobias Petzold, Manuela Thienel, Lisa Dannenberg, Philipp Mourikis, Carolin Helten, Aysel Ayhan, René M'Pembele, Alina Achilles, Kajetan Trojovky, Daniel Konsek, Zhe Zhang, Ron Regenauer, Joachim Pircher, Andreas Ehrlich, Enzo Lüsebrink, Leo Nicolai, Thomas J Stocker, Richard Brandl, Franz Röschenthaler, Jan Strecker, Inas Saleh, Michael Spannagl, Christoph H Mayr, Herbert B Schiller, Christian Jung, Norbert Gerdes, Till Hoffmann, Bodo Levkau, Thomas Hohlfeld, Tobias Zeus, Christian Schulz, Malte Kelm, Amin Polzin |
Journal | Circulation research
(Circ Res)
Vol. 126
Issue 4
Pg. 486-500
(02 14 2020)
ISSN: 1524-4571 [Electronic] United States |
PMID | 31859592
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Factor Xa Inhibitors
- Fibrinolytic Agents
- Platelet Aggregation Inhibitors
- Receptor, PAR-1
- Rivaroxaban
- Factor Xa
|
Topics |
- Animals
- Arteries
(metabolism, pathology)
- Blood Platelets
(drug effects, metabolism)
- Factor Xa
(pharmacology)
- Factor Xa Inhibitors
(pharmacology)
- Fibrinolytic Agents
(administration & dosage, pharmacology)
- Humans
- Mice, Inbred C57BL
- Platelet Activation
(drug effects)
- Platelet Aggregation
(drug effects)
- Platelet Aggregation Inhibitors
(pharmacology)
- Receptor, PAR-1
(agonists, metabolism)
- Rivaroxaban
(administration & dosage, pharmacology)
- Thrombosis
(metabolism, prevention & control)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|